Immune cocktail after transplant shows promise but study halted early
NCT ID NCT02681302
First seen Apr 10, 2026 · Last updated Apr 29, 2026 · Updated 1 time
Summary
This study looked at whether giving two immune-boosting drugs (nivolumab and ipilimumab) after a stem cell transplant could help prevent cancer from coming back in people with high-risk multiple myeloma or lymphoma. The trial enrolled 46 adults aged 18 to 80. The main goal was to check safety and see how well the treatment worked. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hackensack University medical Center
Hackensack, New Jersey, 07601, United States
-
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington D.C., District of Columbia, 20007, United States
Conditions
Explore the condition pages connected to this study.